History of anaesthesia: The ketamine story – past, present and future
The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
The history of ketamine begins in the 1950s at Parke-Davis and Company's laboratories in Detroit, Michigan, USA. At that time, Parke-Davis were searching among cyclohexylamines for an ‘ideal’ anaesthetic agent with analgesic properties. Maddox, a chemist, discovered a process which led to the synthesis of phencyclidine or PCP [N-(1-phenyl-cyclohexyl)-piperidine] on 26 March 1956.1,2 Parke-Davis pharmacologist, Dr Chen, received the compound CI-395 (Fig. 1) from Maddox on 11 September 1958. Chen and, in the same period, Dr Domino,1 began to study the experimental effects of the drug on animals. Phencyclidine created potent analgesia in animals: laparotomies were performed in monkeys without pain, but the animals were in a cataleptic state with their eyes open, and muscle relaxation was of poor quality. Chen3 defined catalepsy as a ‘characteristic akinetic state with a loss of orthostatic reflexes but without impairment of consciousness, in which the extremities appear to be paralysed by motor and sensory failure’.Fig. 1: CI-395, Phencyclidine or N-(1-phenyl-cyclohexyl)-piperidine.Parke-Davis then investigated the potential of phencyclidine as a human anaesthetic under the trade name of Sernyl (Parkes-Davis). In 1958, the first human trials of PCP (Sernyl) were published by Dr Greifenstein (1915 to 1997), professor of anaesthesiology at the Wayne State University, Detroit. PCP caused increases in blood pressure, respiratory rate and minute volume, with conservation of corneal and laryngeal reflexes. The presence of nystagmus and increased salivation were noted. These studies revealed genuine narcosis, with a cataleptic state, potent amnesia and analgesia produced by ketamine anaesthesia.4 Greifenstein and John Stirling Meyer, head of neurology at Wayne State University, concluded that phencyclidine produced a ‘centrally mediated’ sensory deprivation syndrome.1 Surgical incision, and in 30 patients of Greifenstein's series, the complete operation, could be performed under Sernyl alone. But Sernyl was unsatisfactory for surgery in 13 patients, five of whom suffered severe excitation. Ten of the 64 patients were unmanageable in the postoperative period, and some had a very prolonged postoperative recovery (3 to 18 h). It was immediately observed that in no instances did the electroencephalographic (EEG) trace resemble that obtained following the administration of a barbiturate, nor did it resemble the pattern of sleep.4 Johnstone and Evans published their clinical experience in the British Journal of Anaesthesia in 1959.5 They stated that ‘Sernyl was undoubtedly the most potent general analgesic agent which had been used in clinical medicine’. It had the unique advantage over other sedatives and analgesics that it did not cause depression of cardiovascular and respiratory function, nor depression of pharyngeal and laryngeal reflexes, and could be used safely in elderly patients. However, the usefulness of the drug was limited by the excitation which sometimes persisted for more than 12 h after a single dose. The authors spoke of psychotic reactions.5 With growing clinical knowledge, it became clear that phencyclidine was not suitable for human anaesthesia. Eticyclidine, CI-400 or PCE (N-ethyl-1-phenyl-cyclo-hexylamine; Fig. 2), was developed by Parke-Davis in the late 1950s,6 but, because of frequent hallucinations and the concomitant discovery of ketamine, it was not used extensively in clinical practice. The molecule induced a state of catatonia with generalised rigidity and had, like PCP, neither respiratory nor circulatory depressant effects. In 1960, Collins et al. analysed the provided state of consciousness as a kind of trance resulting in a ‘dissociation’ from the environment. On the EEG, delta waves appeared to be related to the analgesic effect. They supposed that the mechanism could possibly be a direct cortical dissociation, or a block of the thalamus or thalamocortical paths.7 PCE was placed into the Schedule I list of illegal drugs in the 1970s.Fig. 2: CI-400, Eticyclidine or N-ethyl-1-phenyl-cyclo-hexylamine.Dr Cal Bratton, head of pharmaceutical research at Parke-Davis, promoted further synthesis of related compounds in the hope of reducing PCP side-effects.1 Calvin Lee Stevens PhD (1923 to 2014) was a chemical consultant to Parke-Davis. He was a professor of organic chemistry at Wayne State University (Detroit, Michigan). Stevens now decided to synthesise a unique series of phencyclidine derivatives in his laboratory. Drs Chen and McCarthy and others,8 screened these in animals, especially monkeys. One of the agents, synthesised in 1962 by Calvin Stevens, produced excellent anaesthesia and was short-acting. It was selected for human trials as CI-581 [2-(O-chloro-phenyl)-2-methyl-amino cyclohexanone],1 and because it was a ketone together with an amine, was named ketamine (Fig. 3). Surprisingly, McCarthy et al.8 described it in 1965 as being a compound with cataleptic, analgesic and anaesthetic a
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Ketamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011442 · Cited by 708
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Pharmacology of Ketamine Isomers in Surgical Patients
White, P. F., Ham, J., Way, W. L., & Trevor, A. (1980) · Anesthesiology · doi:10.1097/00000542-198003000-00008 · Cited by 425
Corssen, G., & Domino, E. F. (1966) · PubMed · Cited by 393
The role of NMDA receptors in learning and memory
Collingridge, G. (1987) · Nature · doi:10.1038/330604a0 · Cited by 370
Research works printed but not linked: 4
- Mangeney, 1971, Ketalar anesthesia; personal experience in 400 cases, Anesth Analg (Paris, 28, 903
- Muhlmann-Weill, 1972, Ketamine-diazepam association in anesthesia, Anesth Analg (Paris, 29, 355
- Sadove, 1971, Clinical study of droperidol in the prevention of the side effects of ketamine anesthesia: a preliminary report, Anesth Analg, 50, 388
- Sofia, 1975, Evaluation of ketamine HCl for antidepressant activity, Arch Int Pharmacodyn Ther, 214, 68
Cited by
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“More recently, it has been found that ketamine, an anesthetic drug first commercially available for human use in 1970 [18, 19], exerts robust, rapid (within 2 h following administration), and sustained (7 days on average) antidepressant actions in patients with major depression, following a single administration (typi…”
BackgroundA historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Metadata
- Authors
- Mion, G.
- Affiliations
- Hôpital Cochin (FR)
- Corresponding author
- Mion, Georges
- ORCID
- Mion, Georges
- Venue
- European Journal of Anaesthesiology
- Published
- 2017-09
- Volume
- 34
- Issue
- 9
- Pages
- 571-575
- ISSN
- 0265-0215 (ISSN-L)
- OpenAlex
- W2737205065
- Cited by
- 113
- References
- 72
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 6 · 2018: 9
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Anaesthesiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Arts and Humanities › History › Medical History and Innovations
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Physiology (medical) › Biomedical and Chemical Research
- Keywords
- ketamine, phencyclidine, history of anesthesia, anesthetic agents, cyclohexylamine, anesthetic side effects, cyclohexylamine derivatives, Parke-Davis, anesthesiology education
- MeSH terms
- Anesthesia, Intravenous, Anesthesiology, Anesthetics, Dissociative, Animals, Humans, Ketamine, Phencyclidine, History, 20th Century, History, 21st Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: History of anaesthesia: The ketamine story – past, present and future. https://app.cochat.ai/papers/10.1097/eja.0000000000000638
- The paper
- Mion, G. (2017). History of anaesthesia: The ketamine story – past, present and future. European Journal of Anaesthesiology. https://doi.org/10.1097/eja.0000000000000638
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.